Oncopeptides publishes disclosure document regarding rights issue

MARKN.

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, ISRAEL, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO BUY SECURITIES IN ONCOPEPTIDES AB (PUBL). SEE ALSO THE SECTION “IMPORTANT INFORMATION” BELOW IN THIS DOCUMENT.

Oncopeptides AB (publ) (“Oncopeptides” or the “Company”) (Nasdaq Stockholm: ONCO) publishes disclosure document in connection with the Company’s new share issue with preferential rights for existing shareholders of approximately SEK 150 million, as resolved by the Board of Directors on 21 August 2025 by virtue of the authorization from the Annual General Meeting held on 22 May 2025 (the “Rights Issue”). The disclosure document has been registered with the Swedish Financial Supervisory Authority and is available at the Company’s website.

Disclosure document
In connection with the Rights Issue, the Company has prepared a disclosure document in accordance with Article 1.4 db of Regulation (EU) 2017/1129 of the European Parliament and of the Council (the “Prospectus Regulation”). The disclosure document has been prepared in accordance with the requirements of Annex IX to the Prospectus Regulation.
 
Today, Oncopeptides announces that the disclosure document has been registered with the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) and is available on the Company’s website www.oncopeptides.com and on www.dnbcarnegie.se.
 
Preliminary timetable for the Rights Issue
The below timetable for the Rights Issue is preliminary and may be adjusted.
 

Record date for right to receive subscription rights28 August 2025
Trading in subscription rights1 – 10 September 2025
Subscription period1 – 15 September 2025
Trading in paid subscribed shares (BTA)1 – 22 September 2025
Announcement of the outcome of the Rights IssueAround 17 September 2025

 
Advisors
DNB Carnegie Investment Bank AB (publ) acts as Sole Global Coordinator and Joint Bookrunner in connection with the Rights Issue. Zonda Partners acts as Joint Bookrunner. Advokatfirman Vinge KB is legal adviser to the Company.

Datum 2025-08-28, kl 08:15
Källa MFN
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 125 000 sidvisningar och 17 000 unika besökare per månad. Vår discord har 7800 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!